Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
20.00
-3.42 (-14.60%)
At close: Nov 3, 2025, 4:00 PM EST
19.66
-0.34 (-1.70%)
After-hours: Nov 3, 2025, 5:49 PM EST
Enliven Therapeutics Employees
Enliven Therapeutics had 62 employees as of December 31, 2024. The number of employees increased by 16 or 34.78% compared to the previous year.
Employees
62
Change (1Y)
16
Growth (1Y)
34.78%
Revenue / Employee
n/a
Profits / Employee
-$1,616,371
Market Cap
1.18B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Dec 31, 2023 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELVN News
- 2 months ago - Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting - PRNewsWire
- 2 months ago - Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - PRNewsWire
- 5 months ago - Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 5 months ago - Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - PRNewsWire
- 5 months ago - Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PRNewsWire
- 5 months ago - Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PRNewsWire
- 5 months ago - Enliven Therapeutics to Present at Upcoming Investor Conferences - PRNewsWire
- 6 months ago - Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - PRNewsWire